{
    "clinical_study": {
        "@rank": "84059", 
        "arm_group": [
            {
                "arm_group_label": "Acthar 40 units", 
                "arm_group_type": "Other", 
                "description": "Acthar 40 units subcutaneously three times a week for patients with sub-nephrotic proteinuria."
            }, 
            {
                "arm_group_label": "Acthar 80 units", 
                "arm_group_type": "Other", 
                "description": "Acthar 80 units subcutaneously twice a week for patients with nephrotic proteinuria."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to determine if the study drug H.C. Acthar gel slows\n      the progression of your kidney disease. This drug is a steroid-based medicine with fewer\n      side effects than other steroids used for treatment of kidney diseases similar to APOL1\n      nephropathy."
        }, 
        "brief_title": "ACTH Treatment of APOL1- Associated Nephropathy", 
        "completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney Disease", 
        "condition_browse": {
            "mesh_term": "Kidney Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non-diabetic African-American with two APOL1-risk genotypes\n\n          -  Age \u226521 years\n\n          -  BMI < 40 kg/m2\n\n          -  Hemoglobin A1c <6.5%\n\n          -  eGFR \u226530 ml/min/1.73m2\n\n          -  Historical urine protein: creatinine ratio \u2265 1.0 g/g\n\n          -  Strong clinical suspicion of APOL1-associated nephropathy or history of biopsy proven\n             focal segmental glomerulosclerosis (FSGS) or focal global glomerulosclerosis (FGGS)\n\n          -  Women of childbearing potential: negative serum pregnancy test at Screening and\n             agreement to follow a medically acceptable form of contraception for the duration of\n             Acthar administration and 4 weeks thereafter\n\n        Exclusion Criteria:\n\n          -  Diagnosis of diabetes mellitus and/or on pharmacologic treatment for diabetes\n\n          -  Medical condition that could cause secondary FSGS\n\n          -  History of sensitivity to steroids (psychosis, steroid-induced diabetes)\n\n          -  Chronic systemic corticosteroid use (Prednisone or equivalent systemic steroid taken\n             for more than 4 consecutive weeks within 6 months prior to screening).\n             Intra-articular, inhaled, and topical steroids are not exclusion criteria.\n\n          -  Contraindication to Acthar per package insert: scleroderma, osteoporosis, systemic\n             fungal infections, ocular herpes simplex, recent surgery (within previous 6 months),\n             history of or the presence of peptic ulcer (within 6 months prior to Screening),\n             adrenal insufficiency or hyperfunction.\n\n          -  Acute glaucoma diagnosed \u22643 months prior to Screening\n\n          -  Biopsy proven glomerular disease other than FSGS or FGGS\n\n          -  Live or live attenuated vaccine received within 1 month prior to screening, or\n             planned administration once enrolled in the study\n\n          -  Uncontrolled hypertension (HTN) (\u2265 180/110 mmHg) and frequent admissions (\u22651\n             admission per 6 months interval) for hypertensive urgency or hypertensive emergency\n\n          -  Unstable cardiovascular disease: history of congestive heart failure (NYHA Functional\n             Class III-IV); history of dilated cardiomyopathy with ejection fraction < 40%; any of\n             the following events within 3 months of screening: unstable angina, myocardial\n             infarction, coronary artery bypass graft or percutaneous transluminal coronary\n             angioplasty, transient ischemic attack or cerebrovascular accident, unstable\n             arrhythmia\n\n          -  Uncontrolled volume overload: history of moderate or severe peripheral edema; on loop\n             diuretics \u2265 120 mg daily of furosemide or \u2265 3.0 mg daily of bumetanide or \u2265 150 mg\n             daily of ethacrynic acid or \u2265 60 mg daily of torsemide;\n\n          -  History of secondary hypertension (i.e., renal artery stenosis, primary aldosteronism\n             or pheochromocytoma)\n\n          -  Significant comorbidities (e.g., advanced malignancy, advanced liver disease) with a\n             life expectancy of less than 1 year\n\n          -  Subject is expected to initiate dialysis within 6 months\n\n          -  Previous treatment on a drug being investigated for the treatment of FSGS\n\n          -  Known diagnosis of Human Immunodeficiency Virus, Hepatitis B, or Hepatitis C\n\n          -  Known history of a primary immunodeficiency or an underlying condition such as\n             splenectomy that predisposes the subject to infections\n\n          -  Systemic hematologic disease (e.g., hematologic malignancy, sickle cell anemia,\n             myelodysplastic syndrome)\n\n          -  Current malignancy or history of malignancy within 5 years of screening, with the\n             exception of non-melanoma skin cancers and cervical intraepithelial neoplasia\n\n          -  Treatment for any malignancy (e.g., radiation, chemotherapy, hormone therapy, or\n             biologics) within 5 years of screening, with the exception of locally excised\n             non-melanoma skin cancer or cervical intraepithelial neoplasia\n\n          -  Pregnant or breast feeding, or might become pregnant during the study or within 4\n             weeks after the end of treatment\n\n          -  Female of reproductive potential not willing to use highly effective methods of birth\n             control during treatment and for 4 weeks after the end of treatment\n\n          -  Currently receiving systemic antibiotics for treatment of an active infection; or\n             history of frequent infections (more than one event per 6  months)\n\n          -  History of any organ transplant\n\n          -  Bipolar disorder, or Major Depressive Disorder characterized by severe depression\n             requiring hospitalization, or history of suicidal ideation/attempts\n\n          -  Currently enrolled in another interventional study, or less than 4 weeks since ending\n             another interventional study(s) or receiving investigational agents(s)\n\n          -  Subject has a disorder that, in the opinion of the investigator, may compromise the\n             ability of the subject to give written informed consent and/or comply with all\n             required study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02006849", 
            "org_study_id": "IRB00024943"
        }, 
        "intervention": {
            "arm_group_label": [
                "Acthar 40 units", 
                "Acthar 80 units"
            ], 
            "description": "FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.", 
            "intervention_name": "Acthar", 
            "intervention_type": "Drug", 
            "other_name": "Repository Corticotropin"
        }, 
        "intervention_browse": {
            "mesh_term": "Adrenocorticotropic Hormone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "AfricanAmericans", 
            "Hypertension", 
            "Proteinuria", 
            "ApoL1 gene"
        ], 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Winston-Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157"
                }, 
                "name": "Wake Forest Baptist Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "ACTH Treatment of APOL1- Associated Nephropathy", 
        "overall_contact": {
            "email": "mmurea@wakehealth.edu", 
            "last_name": "Mariana Murea, MD", 
            "phone": "336 716-4650"
        }, 
        "overall_contact_backup": {
            "email": "mhspain@wakehealth.edu", 
            "last_name": "Mitzie Spainhour, LPN", 
            "phone": "336 716-4246"
        }, 
        "overall_official": {
            "affiliation": "Wake Forest School of Medicine", 
            "last_name": "Mariana Murea, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Complete remission (CR) (UPCR <0.2g/g) or partial remission (PR) (50% drop in UPCR from baseline) of proteinuria at the end of Treatment period in patients with baseline nephrotic proteinuria", 
                "measure": "Change in proteinuria with H.C. Acthar gel", 
                "safety_issue": "No", 
                "time_frame": "End of treatment with H.C. Acthar gel (end of 6 months or 1 year of treatment)"
            }, 
            {
                "description": "Percent change in proteinuria at the end of Treatment period in patients with baseline sub-nephrotic proteinuria", 
                "measure": "Change in proteinuria with H.C. Acthar gel", 
                "safety_issue": "No", 
                "time_frame": "End of treatment with H.C. Acthar gel (end of 6 months or 1 year of treatment)"
            }, 
            {
                "description": "Percent change in Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR at the end of Treatment period", 
                "measure": "Change in eGFR with H.C. Acthar gel", 
                "safety_issue": "No", 
                "time_frame": "End of treatment with H.C. Acthar gel (end of 6 months or 1 year of treatment)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02006849"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wake Forest School of Medicine", 
            "investigator_full_name": "Mariana Murea, MD", 
            "investigator_title": "Assistant Professor, Internal Medicine/Nephrology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Percent change in proteinuria after 1 year and  2 years of follow-up", 
                "measure": "Percent change in proteinuria", 
                "safety_issue": "No", 
                "time_frame": "1 year and 2 years of study follow-up after treatment completion"
            }, 
            {
                "description": "Percent change in CKD-EPI eGFR at 1 and 2 years of study follow-up", 
                "measure": "Percent change in CKD-EPI eGFR", 
                "safety_issue": "No", 
                "time_frame": "1 year and 2 years of study follow-up after treatment completion"
            }, 
            {
                "description": "Change in eGFR over time, based on baseline proteinuria (nephrotic vs. sub-nephrotic), baseline eGFR (eGFR 30-45 vs. eGFR 45-59), and Acthar dose", 
                "measure": "Change in CKD-EPI eGFR", 
                "safety_issue": "No", 
                "time_frame": "1 year and 2 years of study follow-up after treatment completion"
            }, 
            {
                "description": "Proportion of patients with baseline nephrotic proteinuria who sustained CR or PR at 1 and 2 years of study follow-up", 
                "measure": "Duration of remission after H.C. Acthar gel treatment", 
                "safety_issue": "No", 
                "time_frame": "1 year and 2 years of study follow-up after treatment completion"
            }, 
            {
                "description": "Modifications in kidney histopathology on second post-treatment kidney biopsy (% glomerulosclerosis, % tubulointerstitial fibrosis, restoration of podocyte markers [e.g.,podocin, synaptopodin, Wilms tumor 1]) compared with baseline biopsy", 
                "measure": "Changes in kidney fibrosis after H.C. Acthar gel treatment", 
                "safety_issue": "No", 
                "time_frame": "End of treatment with H.C. Acthar gel (end of 6 months or 1 year of treatment)"
            }, 
            {
                "description": "Changes in cholesterol and lipoprotein levels compared with baseline profiles", 
                "measure": "Cholesterol and lipoprotein profile before and after treatment with H.C. Acthar gel", 
                "safety_issue": "No", 
                "time_frame": "End of treatment with H.C. Acthar gel (end of 6 months or 1 year of treatment)"
            }
        ], 
        "source": "Wake Forest School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wake Forest School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}